Sugi Predict

Sugi Predict / Compounds / SCHEMBL1497755

SCHEMBL1497755

SCHEMBL1497755

CC(C)(C)OC(=O)N1CCC[C@@H](n2nc(I)c3c(N)ncnc32)C1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 9/20 0.68
▸ JAK2 O60674 5/20 0.68
▸ JAK3 P52333 4/20 0.68
▸ BTK Q06187 3/20 0.54
▸ JAK1 P23458 3/20 0.53
▸ SRC P12931 6/20 0.53
▸ KDR P35968 2/20 0.52
▸ CDC7 O00311 1/20 0.52
▸ PLK4 O00444 1/20 0.52
▸ DYRK3 O43781 1/20 0.52
▸ PRKD3 O94806 1/20 0.52
▸ MAP4K4 O95819 1/20 0.52
▸ NTRK1 P04629 1/20 0.52
▸ INSR P06213 1/20 0.52
▸ LCK P06239 1/20 0.52
▸ FYN P06241 1/20 0.52
▸ CDK1 P06493 1/20 0.52
▸ RET P07949 1/20 0.52
▸ ROS1 P08922 1/20 0.52
▸ FER P16591 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1497754 1.00 EGFR (0.68) EGFRJAK2JAK3BTKJAK1
SCHEMBL4823191 1.00 EGFR (0.68) EGFRJAK2JAK3BTKJAK1
SCHEMBL29351446 1.00 EGFR (0.68) EGFRJAK2JAK3BTKJAK1
SCHEMBL29671261 1.00 EGFR (0.68) EGFRJAK2JAK3BTKJAK1
SCHEMBL14706373 0.94 EGFR (0.60) EGFRJAK2JAK3BTKJAK1
SCHEMBL29799663 0.94 EGFR (0.60) EGFRJAK2JAK3BTKJAK1
SCHEMBL31574063 0.94 EGFR (0.60) EGFRJAK2JAK3BTKJAK1
SCHEMBL4824842 0.94 EGFR (0.60) EGFRJAK2JAK3BTKJAK1
SCHEMBL29588418 0.94 EGFR (0.60) EGFRJAK2JAK3BTKJAK1
SCHEMBL15345583 0.94 EGFR (0.60) EGFRJAK2JAK3BTKJAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113968860-A Reversible BTK inhibitor and synthesis method and application thereof 杭州医学院 2022-01-25 — — CN claimed
EP-3181567-B9 PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2025-09-24 — — EP disclosed
EP-3590516-B1 ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND TAIHO PHARMACEUTICAL CO LTD (JP) 2025-09-03 — — EP disclosed
US-20240174676-A1 Pyrazolopyrimidine compounds as kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2024-05-30 — — US disclosed
CN-115160319-B Compound containing 1, 3-benzodioxolane structure and preparation method and application thereof 西安新通药物研究股份有限公司 2023-12-26 — — CN disclosed
US-11696917-B2 Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound TAIHO PHARMACEUTICAL CO., LTD. (JP) 2023-07-11 — — US disclosed
US-11696917-B2 Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound TAIHO PHARMACEUTICAL CO., LTD. (JP) 2023-07-11 — — US disclosed
CN-114213416-B Irreversible BTK inhibitor with oxazolo [4,5-b ] pyridine structure and application thereof 杭州医学院 2023-06-06 — — CN disclosed
CN-114213416-A Irreversible BTK inhibitor with oxazolo [4,5-b ] pyridine structure and application thereof 杭州医学院 2022-03-22 — — CN disclosed
US-20220073522-A1 Substituted Pyrazolo[3,4-d]Pyrimidines as Kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2022-03-10 — — US disclosed
WO-2014022569-A1 TREATMENT OF DRY EYE PRINCIPIA BIOPHARMA INC. (US) 2014-02-06 — — WO disclosed
CN-103534258-A Tyrosine kinase inhibitors PRINCIPIA BIOPHARMA INC 2014-01-22 — — CN disclosed
WO-2012158795-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2012-11-22 — — WO disclosed
WO-2012158843-A2 KINASE INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-11-22 — — WO disclosed
EP-2475375-A2 PI3 KINASE INHIBITORS AND USES THEREOF Avila Therapeutics, Inc. (US) 2012-07-18 — — EP disclosed
US-20110230476-A1 PI3 KINASE INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2011-09-22 — — US disclosed
US-20110230476-A1 PI3 KINASE INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2011-09-22 — — US disclosed
US-20110230476-A1 PI3 KINASE INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2011-09-22 — — US disclosed
WO-2011031896-A2 PI3 KINASE INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2011-03-17 — — WO disclosed
WO-2011031896-A2 PI3 KINASE INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2011-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11696917-B2 Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound ZYX, DPYD, ZFX EGFR 2082/4885JAK2 93/4885JAK3 196/4885
US-20110230476-A1 PI3 KINASE INHIBITORS AND USES THEREOF PIK3CA, PIK3CB, PIK3C2B EGFR 580/4885JAK2 47/4885JAK3 65/4885
US-20220073522-A1 Substituted Pyrazolo[3,4-d]Pyrimidines as Kinase Inhibitors BTK, SYK, LCK EGFR 555/4885JAK2 8/4885JAK3 9/4885
US-20240174676-A1 Pyrazolopyrimidine compounds as kinase Inhibitors BTK, LCK, LYN EGFR 575/4885JAK2 7/4885JAK3 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.